Christiaan De Wilde succeeds Frank Morich as Innogenetics' CEO
The Innogenetics Board of Directors has named Chief Financial Officer (CFO) Christiaan De Wilde as the company's Chief Executive Officer (CEO), following the resignation of Frank Morich to pursue other interests. Christiaan has served as CFO of Innogenetics and a member of its Management Committee since August 2006.
Christiaan De Wilde will start his new assignment effective October 15th, 2007. He brings to this position a wealth of senior executive experience in financial controlling and business strategy. Prior to joining Innogenetics in 2006, Christiaan built a 17-year career at Johnson & Johnson and served at different senior executive positions, including as Finance & Logistics Director Benelux of Johnson & Johnson Medical from June 2000 until May 2005. He was appointed Member of the Board of Directors at Janssen-Cilag Belgium NV in May 2005.
The Board has begun a search for a permanent replacement CFO and expects to complete the search by year end. Christiaan De Wilde will act in a joint capacity as CEO and CFO during the interim period.
Other news from the department people
